Prognostic scores are valuable tools for predicting survival in patients with chronic liver disease. Recently, the albumin-bilirubin (ALBI) score has emerged as a potential prognostic indicator in ...
The primary combined endpoint occurred in 26.8% of patients in the rivaroxaban group vs 46.9% of those in the placebo group, with 1-year survival probabilities of 78.7% vs 54.4% and 2-year survival ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback